Lantheus Holdings (LNTH) has entered into a definitive agreement to acquire Evergreen Theragnostics, Inc. This transaction is structured as an all-cash deal, featuring an upfront payment of $250 million and the possibility of additional milestone payments totaling up to $752.5 million.
Evergreen Theragnostics operates as a clinical-stage radiopharmaceutical company, offering both Contract Development and Manufacturing services, and engaging in drug discovery and commercialization of its proprietary products. Situated in Springfield, NJ, Evergreen's operations are housed in a modern GMP-certified radiopharmaceutical facility.
In addition to this acquisition announcement, Lantheus Holdings has reaffirmed its financial guidance for both the full year and fourth quarter of 2024.
